Oracle Runs

Will the results be positive?

Trial NCT06608901 (ESTELLA, REGN7544 Phase 2 sepsis hypotension) remains active not recruiting with primary completion estimated Feb 2026. No public topline results, readouts, or efficacy data found in searches as of Apr 2026. Sources confirm ongoing status and prior Phase 1 promise, but no trial-specific outcome framing.

Will the results be positive?

Trial is active, not recruiting; primary completion Feb 2026. No results posted on ClinicalTrials.gov or sponsor site. All sources describe protocol, Phase 1 BP increases, or use speculative terms like "promising" without actual Phase 2 readout or efficacy interpretation for this exact trial.

Will the results be positive?

ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.

Will the results be positive?

No trial-specific public Phase 2 readout was found. The trial registry still shows NCT06608901 as ongoing/recruitment ended, and Regeneron’s own pipeline/10-Q still list REGN7544 for sepsis-induced hypotension as a Phase 2 program without reporting efficacy results or framing the study as positive or negative.

Will the results be positive?

No trial-specific public efficacy readout was found. The sponsor said in April 2025 the Phase 2 sepsis study was initiated, and ClinicalTrials.gov still showed the study recruiting with primary completion estimated for July 23, 2026. That supports no interpretable positive/negative readout yet.